Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Novartis
Johnson and Johnson
Cipla
Teva
Chinese Patent Office
Deloitte
Colorcon
McKinsey

Generated: October 20, 2017

DrugPatentWatch Database Preview

SANOFI AVENTIS US Company Profile

« Back to Dashboard

What is the competitive landscape for SANOFI AVENTIS US, and when can generic versions of SANOFI AVENTIS US drugs launch?

SANOFI AVENTIS US has one hundred and thirty-six approved drugs.

There are fifty-seven US patents protecting SANOFI AVENTIS US drugs.

There are one thousand and fifty patent family members on SANOFI AVENTIS US drugs in seventy-four countries and one hundred and forty-seven supplementary protection certificates in fifteen countries.

Summary for Applicant: SANOFI AVENTIS US

International Patents:1050
US Patents:57
Tradenames:113
Ingredients:93
NDAs:136
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
PRIMACOR
milrinone lactate
INJECTABLE;INJECTION019436-001Dec 31, 1987DISCNYesNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL021704-002Jan 24, 2011OTCYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
APIDRA SOLOSTAR
insulin glulisine recombinant
INJECTABLE;SUBCUTANEOUS021629-003Feb 24, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
LANTUS SOLOSTAR
insulin glargine recombinant
INJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
NASACORT ALLERGY 24 HOUR
triamcinolone acetonide
SPRAY, METERED;NASAL020468-002Oct 11, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
LOVENOX (PRESERVATIVE FREE)
enoxaparin sodium
INJECTABLE;SUBCUTANEOUS020164-002Jan 30, 1998APRXYesNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
NASACORT ALLERGY 24 HOUR
triamcinolone acetonide
SPRAY, METERED;NASAL020468-002Oct 11, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
DIABETA
glyburide
TABLET;ORAL017532-002May 1, 1984AB2RXYesNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
SUSPENSION;ORAL201373-001Jan 24, 2011OTCYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
BRICANYL
terbutaline sulfate
TABLET;ORAL017618-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sanofi Aventis Us

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
BRICANYL
terbutaline sulfate
INJECTABLE;INJECTION017466-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-001Jan 31, 2005► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA HIVES
fexofenadine hydrochloride
TABLET;ORAL020872-008Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
SUSPENSION;ORAL201373-001Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
LORELCO
probucol
TABLET;ORAL017535-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA HIVES
fexofenadine hydrochloride
TABLET;ORAL020872-008Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-003Nov 17, 2006► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA HIVES
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909-003Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
INTAL
cromolyn sodium
CAPSULE;INHALATION016990-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
AVAPRO
irbesartan
TABLET;ORAL020757-001Sep 30, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SANOFI AVENTIS US drugs

Drugname Dosage Strength Tradename Submissiondate
nicotine
Transdermal System7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs
NICODERM CQ
5/30/2014
dronedarone hydrochloride
Tablets400 mg
MULTAQ
7/1/2013
oxaliplatin
Injection5 mg/mL, 40 mL vial
ELOXATIN
3/23/2011
fexofenadine hydrochloride
Oral Suspension30 mg/5 mL
ALLEGRA
1/25/2010
docetaxel
Injection40 mg/mL, 0.5 mL and 2 mL vials
TAXOTERE
6/30/2009
clopidogrel bisulfate
Tablets300 mg
PLAVIX
3/4/2009
oxaliplatin
Injection200 mg/40 mL
ELOXATIN
7/16/2007
oxaliplatin
Injection5 mg/mL, 10 mL and 20 mL vials
ELOXATIN
2/9/2007
oxaliplatin
For Injection50 mg/vial and 100 mg/vial
ELOXATIN
2/9/2007
enoxaparin sodium
Injection100 mg/mL, 3 mL vials
LOVENOX
12/7/2006
irbesartan and hydrochlorothiazide
Tablets300 mg/25 mg
AVALIDE
6/6/2006
zolpidem tartrate
Extended-release Tablets6.25 mg
AMBIEN CR
2/24/2006
zolpidem tartrate
Extended-release Tablets12.5 mg
AMBIEN CR
1/19/2006
irbesartan and hydrochlorothiazide
Tablets150 mg/12.5 mg and 300 mg/12.5 mg
AVALIDE
11/10/2004
irbesartan
Tablets75 mg, 150 mg and 300 mg
AVAPRO
5/25/2004

Premature patent expirations for SANOFI AVENTIS US

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Sanofi Aventis Us

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,905,867Pen-type injector► Subscribe
6,218,553 Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor► Subscribe
8,070,727Drive mechanisms suitable for use in drug delivery devices► Subscribe
7,147,870Osmotic device containing pseudoephedrine and an H1 antagonist► Subscribe
6,187,791 Method of providing an antihistaminic effect in a hepatically impaired patient► Subscribe
7,205,276Zinc-free and low-zinc insulin preparations having improved stability► Subscribe
6,100,404 Erythromycin compounds► Subscribe
9,526,843Drive mechanisms suitable for use in drug delivery devices► Subscribe
6,372,780 Methods of treating cell lines expressing multidrug resistance P-glycoprotein► Subscribe
6,046,322 Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5%► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sanofi Aventis Us Drugs

Country Document Number Estimated Expiration
Australia8220398► Subscribe
China100443128► Subscribe
China1273187► Subscribe
Slovakia19092000► Subscribe
Iceland5317► Subscribe
Slovakia281707► Subscribe
Hungary229266► Subscribe
Serbia51135► Subscribe
Portugal1603610► Subscribe
Norway20013012► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sanofi Aventis Us Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90018-6Sweden► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
C/GB97/078United Kingdom► SubscribePRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
C0036Belgium► SubscribePRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
2014 00005Denmark► SubscribePRODUCT NAME: TERIFLUNOMID, DETS STEREOISOMER OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/13/838/001-005 20130826
636Luxembourg► SubscribePRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
C0020France► SubscribePRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: LI - 56370 20031110
13/034Ireland► SubscribeAPPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE 2013/034 IN JOURNAL NO. 2325 OF 25/01/2017 UNDER THE HEADING APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE, SPC NO. 2013/034 SHOULD HAVE APPEARED AS FOLLOWS, NOVO NORDISK A/S NOVO ALLE, 2880 BAGSVAERD, DENMARK (20/12/2016) PATENT NO: EP2107069; NOVEL INSULIN DERIVATIVES PRODUCT: INSULIN DEGLUDEC MARKET AUTHORISATION: EU: EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 (21/01/2013) ORIGINAL SPC EXPIRY DATE: 22/01/2028 1127 DESIGNS REGISTERED UNDER THE INDUSTRIAL DESIGNS ACT, 2001
90025-3Sweden► SubscribePRODUCT NAME: CABAZITAXEL ACETONSOLVAT; REG. NO/DATE: EU/1/11/676/001 20110317
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Deloitte
Citi
Accenture
Cipla
Julphar
Cantor Fitzgerald
Harvard Business School
Healthtrust
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot